In the present pilot study, our aim was to explore whether adjunct therapy with an empagliflozin/metformin combination or separate drugs could beneficially complement insulin therapy and allow greater glycemic control and beneficial metabolic effects in overweight people with type 1 diabetes with increased cardiovascular risk. This evidence concerns the gene INS and type 1 diabetes mellitus.